---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-023207"
form_type: "8-K"
ticker: "VYCO"
cik: "0001424768"
company_name: "VYCOR MEDICAL INC"
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:49:47.693634+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vycor Medical Q3 revenue $514K (+31% YoY); posts GAAP operating profit of $32K

## Summary
- Q3 2025 revenue $513,792, up 31% YoY; Vycor Medical division up 32% to $492K, mostly US growth.
- GAAP operating profit of $32,085 in Q3 vs. loss in prior year; non-GAAP operating profit $60,162.
- Nine-month revenue $1,446,523 (+28% YoY); non-GAAP operating profit $166,262 vs. $27,021 in 2024.
- Gross margin dipped to 88% (Q3) and 84% (9-month) from 90% due to validation costs and international mix.
- Three new peer-reviewed papers on VBAS published; NeuroEyeCoach study validates home-based therapy.

## SEC filing metadata
- accession: 0001493152-25-023207
- form_type: 8-K
- ticker: VYCO
- cik: 0001424768
- company_name: VYCOR MEDICAL INC
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1424768/000149315225023207/0001493152-25-023207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1424768/000149315225023207/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-023207
- JSON: https://secwatch.observer/filing/0001493152-25-023207.json
- Plain text: https://secwatch.observer/filing/0001493152-25-023207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.